A prospective phase I and consecutive phase II, two arm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma.

Trial Profile

A prospective phase I and consecutive phase II, two arm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Temsirolimus (Primary) ; Dacarbazine; Etoricoxib; Pioglitazone; Trofosfamide
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Planned end date 1 May 2016 added as reported by ClinicalTrials.gov.
    • 05 Jun 2012 New source identified and integrated (NCT01614301: ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top